Detalhe da pesquisa
1.
Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns and their modulation by therapeutic peptides.
Curr Med Chem
; 12(13): 1537-50, 2005.
Artigo
Inglês
| MEDLINE | ID: mdl-15974986
2.
Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
J Med Chem
; 48(5): 1470-80, 2005 Mar 10.
Artigo
Inglês
| MEDLINE | ID: mdl-15743189
3.
Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
Eur J Med Chem
; 101: 13-23, 2015 Aug 28.
Artigo
Inglês
| MEDLINE | ID: mdl-26112377
4.
Immunotherapy for multiple sclerosis: basic insights for new clinical strategies.
Curr Neurovasc Res
; 1(4): 325-40, 2004 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-16181082
5.
Current therapeutic leads for the treatment of autoimmune diseases: stem cell transplantation and inhibition of post-translational modifications of autoantigens.
Expert Opin Drug Discov
; 3(10): 1255-65, 2008 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23489081
6.
Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP(87-99)) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease.
J Med Chem
; 51(24): 7834-42, 2008 Dec 25.
Artigo
Inglês
| MEDLINE | ID: mdl-19053745
7.
Anti-TNF-alpha antibody therapies in autoimmune diseases.
Curr Top Med Chem
; 6(16): 1707-14, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-17017952
8.
Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS) In vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients.
J Autoimmun
; 23(2): 169-77, 2004 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-15324935